TFX vs ICU vs UTMD vs ATRC vs NVCR

For growth investors, AtriCure, Inc.

(ATRC) is the stronger pick with 14. 9% revenue growth year-over-year, versus -34. 6% for Teleflex Incorporated (TFX). Utah Medical Products, Inc. (UTMD) offers the better valuation at 18. 8x trailing P/E (10. 4x forward), making it the more compelling value choice. Analysts rate Teleflex Incorporated (TFX) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Utah Medical Products, Inc.

is actually cheaper at 10. 4x.

Over the past 5 years, Utah Medical Products, Inc.

(UTMD) delivered a total return of -18. 2%, compared to -98. 1% for SeaStar Medical Holding Corporation (ICU). Over 10 years, the gap is even starker: ATRC returned +95. 1% versus ICU's -98. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Utah Medical Products, Inc.

(UTMD) is the lower-risk stock at 0. 55β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 298% more volatile than UTMD relative to the S&P 500. On balance sheet safety, Utah Medical Products, Inc. (UTMD) carries a lower debt/equity ratio of 0% versus 87% for Teleflex Incorporated — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AtriCure, Inc.

(ATRC) is pulling ahead at 14. 9% versus -34. 6% for Teleflex Incorporated (TFX). On earnings-per-share growth, the picture is similar: SeaStar Medical Holding Corporation grew EPS 78. 1% year-over-year, compared to -1468. 2% for Teleflex Incorporated. Over a 3-year CAGR, ATRC leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Utah Medical Products, Inc.

(UTMD) is the more profitable company, earning 29. 3% net margin versus -183. 9% for SeaStar Medical Holding Corporation — meaning it keeps 29. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UTMD leads at 29. 6% versus -132. 2% for ICU. At the gross margin level — before operating expenses — ICU leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Utah Medical Products, Inc.

(UTMD) trades at 10. 4x forward P/E versus 370. 7x for AtriCure, Inc. — 360. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

In this comparison, UTMD (1.

9% yield), TFX (1. 0% yield) pay a dividend. ICU, ATRC, NVCR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Utah Medical Products, Inc.

(UTMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 55), 1. 9% yield). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (UTMD: +19. 1%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

TFX, UTMD pay a dividend while ICU, ATRC, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.